newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical